Dynavax Technologies (DVAX) Slammed on CRL; Is it Now a Bounce Candidate?
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Dynavax (DVAX) Receives CRL from FDA on HEPLISAV
February 25, 2013 6:50 AM ESTDynavax Technologies Corporation (NASDAQ: DVAX) announced Monday that it received a Complete Response Letter (CRL) from the FDA regarding its Biologic License Application (BLA) for HEPLISAV, an investigational adult hepatitis B vaccine.
In the CRL, the FDA specified that the indication in adults 18-70 years of... More
Jefferies Would Still Buy Dynavax Technologies (DVAX) if CRL Issued Friday
February 21, 2013 12:20 PM ESTJefferies reiterated ts Buy rating and $5 price target on Dynavax Technologies (NASDAQ: DVAX) ahead of Friday's Heplisav FDA decision.
"We have revised our scenarios for Fridays Heplisav FDA decision and added a scenario in which the company receives a complete... More
